Rollout of Moderna vaccine begins as AstraZeneca children’s trial is paused
A third coronavirus vaccine is being rolled out in the UK, as investigations continue into a potential association between the Oxford/AstraZeneca jab and a rare form of blood clot.
People in Wales will receive the first doses of the Moderna vaccine on Wednesday, April 7, in what has been hailed as “another key milestone” in the fight against coronavirus.
The UK has bought 17 million doses of that vaccine – enough for 8.5 million people – with the rollout in England to start “as soon as possible this month”, according to a Department of Health and Social Care spokesman.
More than 31 million first doses of either the Pfizer or AstraZeneca vaccines have been administered in the UK, according to Government data up to April 5, while more than five million second doses have been given out.
It comes as a trial of the Oxford/AstraZeneca vaccine in children has been paused while regulators investigate reports of a rare form of blood clot among adults.
The University of Oxford said no safety concerns have arisen from the children’s trial and Sage adviser Professor Calum Semple said the decision to pause had been made out of “exceptional caution”, as he urged people to continue accepting Oxford/AstraZeneca jabs.
Assessments are under way into a very rare and specific type of blood clot in the brain, known as cerebral venous sinus thrombosis (CVST), occurring together with low levels of platelets (thrombocytopenia) following vaccination in adults.
The World Health Organisation (WHO) and the European Medicines Agency (EMA) are expected to announce findings of their assessments on Wednesday or Thursday.
The UK’s regulator – the Medicines and Healthcare products Regulatory Agency (MHRA) – is also investigating reports but has not confirmed when it will present its findings.
Both the MHRA – which said it had identified 30 cases of rare blood clot events out of 18.1 million doses of the jab administered up to and including March 24 – and WHO have said that to date the benefits of the vaccine in preventing coronavirus outweigh any risks.
Dr Maggie Wearmouth, a member of the Joint Committee on Vaccination and Immunisation (JCVI), indicated that “perhaps slowing things down” with the rollout “until we’re absolutely certain” might be wise.